Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Highly active RMS as defined by:~* One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)~* Two or more relapses in the previous year, whether on DMD treatment or not.~* Expanded Disability Status Scale (EDSS) score less than equals to (\<=) 5.0.~* Other protocol defined inclusion criteria could apply.~Exclusion Criteria:~* Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.~* Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).~* Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.~* Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.~* History of tuberculosis , presence of active tuberculosis, or latent tuberculosis~* Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).~* Active malignancy or history of malignancy.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mavenclad® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).